title: Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.
abstract: Transthyretin (TTR)-associated amyloidosis is a late-onset autosomal-dominant genetic disease. Over 100 amyloidogenic mutations have been identified in TTR which destabilize the TTR tetramer thereby inducing the formation of amyloid fibrils in tissues such as the heart and peripheral nerves. This disease mainly affects peripheral nerves, causing familial amyloid polyneuropathy (FAP) or heart, causing familial amyloid cardiomyopathy (FAC). Circulating TTR is predominantly produced by liver, and the only widely available clinical treatment for FAP is orthotopic liver transplantation (OLT), whereas no treatment currently exists for FAC. Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. When tested in a human TTR transgenic mouse model (hTTR Ile84Ser), ISIS-TTR(Rx) showed a dose-dependent reduction of human TTR (up to >80%) at both the mRNA and protein levels. In cynomolgus monkeys, ISIS-TTR(Rx) treatment produced a time-dependent reduction in plasma TTR levels. After 12 weeks of treatment in monkey, liver TTR mRNA and plasma TTR protein levels were reduced by ~80%. As expected, treatment with ISIS-TTR(Rx) also produced a significant decrease in plasma RBP4 levels that correlated with reductions in TTR levels. ISIS-TTR(Rx) treatment was well tolerated in both rodents and monkeys and produced a PK/PD profile consistent with prior experiences using this chemistry platform. ISIS-TTR(Rx) is currently under evaluation in a Phase 1 clinical trial in normal healthy volunteers, and interim results of this trial will be presented.
authors.affiliation: Department of Antisense Drug Discovery and Clinical Development, Isis Pharmaceuticals, Carlsbad, CA, USA.
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Ackermann
authors.forename: Shuling
authors.initials: S
authors.lastname: Guo
authors.forename: Sheri
authors.initials: S
authors.lastname: Booten
authors.forename: Luis
authors.initials: L
authors.lastname: Alvarado
authors.forename: Merrill
authors.initials: M
authors.lastname: Benson
authors.forename: Steve
authors.initials: S
authors.lastname: Hughes
authors.forename: Brett P
authors.initials: BP
authors.lastname: Monia
mesh_terms: D028227:Amyloid Neuropathies, Familial / Q000235:genetics* / Q000628:therapy*; D000818:Animals; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D016376:Oligonucleotides, Antisense / Q000235:genetics*; D011228:Prealbumin / Q000235:genetics*
chemical_list: D016376:Oligonucleotides, Antisense; D011228:Prealbumin